244 related articles for article (PubMed ID: 30312726)
1. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution.
Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H
Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726
[TBL] [Abstract][Full Text] [Related]
2. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.
Huang HC; Shi J; Orth JD; Mitchison TJ
Cancer Cell; 2009 Oct; 16(4):347-58. PubMed ID: 19800579
[TBL] [Abstract][Full Text] [Related]
3. Second-Generation Antimitotics in Cancer Clinical Trials.
Novais P; Silva PMA; Amorim I; Bousbaa H
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371703
[TBL] [Abstract][Full Text] [Related]
4. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.
Schmidt M; Bastians H
Drug Resist Updat; 2007; 10(4-5):162-81. PubMed ID: 17669681
[TBL] [Abstract][Full Text] [Related]
5. Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
Giovinazzi S; Bellapu D; Morozov VM; Ishov AM
Cell Cycle; 2013 Aug; 12(16):2598-607. PubMed ID: 23907120
[TBL] [Abstract][Full Text] [Related]
6. Target driven preclinical screening for new antimitotic chemotherapy agents.
Novío S; Freire-Garabal M; Núñez MJ
Curr Top Med Chem; 2014; 14(20):2263-71. PubMed ID: 25434356
[TBL] [Abstract][Full Text] [Related]
7. Mitosis and apoptosis: how is the balance set?
Topham CH; Taylor SS
Curr Opin Cell Biol; 2013 Dec; 25(6):780-5. PubMed ID: 23890995
[TBL] [Abstract][Full Text] [Related]
8. A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel.
França F; Silva PMA; Soares JX; Henriques AC; Loureiro DRP; Azevedo CMG; Afonso CMM; Bousbaa H
Molecules; 2020 Dec; 25(24):. PubMed ID: 33322077
[TBL] [Abstract][Full Text] [Related]
9. Kinesin motor proteins as targets for cancer therapy.
Huszar D; Theoclitou ME; Skolnik J; Herbst R
Cancer Metastasis Rev; 2009 Jun; 28(1-2):197-208. PubMed ID: 19156502
[TBL] [Abstract][Full Text] [Related]
10. The mitotic checkpoint in cancer therapy.
Tao W
Cell Cycle; 2005 Nov; 4(11):1495-9. PubMed ID: 16258280
[TBL] [Abstract][Full Text] [Related]
11. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.
Harrison MR; Holen KD; Liu G
Clin Adv Hematol Oncol; 2009 Jan; 7(1):54-64. PubMed ID: 19274042
[TBL] [Abstract][Full Text] [Related]
12. Consequences of mitotic slippage for antimicrotubule drug therapy.
Cheng B; Crasta K
Endocr Relat Cancer; 2017 Sep; 24(9):T97-T106. PubMed ID: 28684541
[TBL] [Abstract][Full Text] [Related]
13. Targeting mitosis for anti-cancer therapy.
Sudakin V; Yen TJ
BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
[TBL] [Abstract][Full Text] [Related]
14. Antagonizing the spindle assembly checkpoint silencing enhances paclitaxel and Navitoclax-mediated apoptosis with distinct mechanistic.
Henriques AC; Silva PMA; Sarmento B; Bousbaa H
Sci Rep; 2021 Feb; 11(1):4139. PubMed ID: 33603057
[TBL] [Abstract][Full Text] [Related]
15. Targeting mitotic exit for cancer treatment.
Wäsch R
Expert Opin Ther Targets; 2011 Jul; 15(7):785-8. PubMed ID: 21476883
[TBL] [Abstract][Full Text] [Related]
16. Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Penna LS; Henriques JAP; Bonatto D
Pharmacol Ther; 2017 May; 173():67-82. PubMed ID: 28174095
[TBL] [Abstract][Full Text] [Related]
17. Adapt or die: how eukaryotic cells respond to prolonged activation of the spindle assembly checkpoint.
Rossio V; Galati E; Piatti S
Biochem Soc Trans; 2010 Dec; 38(6):1645-9. PubMed ID: 21118141
[TBL] [Abstract][Full Text] [Related]
18. Spindle poisons and cell fate: a tale of two pathways.
Matson DR; Stukenberg PT
Mol Interv; 2011 Apr; 11(2):141-50. PubMed ID: 21540474
[TBL] [Abstract][Full Text] [Related]
19. Natural products as new antimitotic compounds for anticancer drug development.
Paier CRK; Maranhão SS; Carneiro TR; Lima LM; Rocha DD; Santos RDS; Farias KM; Moraes-Filho MO; Pessoa C
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e813s. PubMed ID: 30540125
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in discovery and development of antimitotic agents.
Kiselyov A; Balakin KV; Tkachenko SE; Savchuk N; Ivachtchenko AV
Anticancer Agents Med Chem; 2007 Mar; 7(2):189-208. PubMed ID: 17348827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
